$ANRO News

Alto Neuroscience Promotes Nick Smith To President, CFO, Effective Aug. 26

HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $55

Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?

Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?

Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans

Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $26

BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate

Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Alto Neuroscience Prices ~$100M Offering Of 3.776M Common Shares At $26.48/Share

Alto Neuroscience Intends To Accelerate And Expand Clinical Development Of ALTO-207, Including An Additional Planned Phase 3 Trial As Monotherapy For Treatment-Resistant Depression

Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Alto Neuroscience Publishes Trial Of Dopamine Agonist Pramipexole With Mood Disorders And Clinically Significant Anhedonia In Nature Medice

Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36

Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $24

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate